We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Simulations Plus Inc (SLP) Com USD0.001

Sell:$41.70 Buy:$41.82 Change: $0.05 (0.12%)
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
Change: $0.05 (0.12%)
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
Change: $0.05 (0.12%)
Market closed |  Prices as at close on 23 February 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. The Company's segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. Its software and consulting services are provided to various industries, including biotechnology and cosmetics.

Contact details

42505 10Th Street West
United States
+1 (661) 7237723

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$822.64 million
Shares in issue:
19.97 million
Health Care Technology
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Shawn O'Connor
    Chief Executive Officer
  • William Frederick
    Chief Financial Officer, Chief Operating Officer, Secretary
  • John Dibella
    President - PBPK, Regulatory Strategies, Cheminformatics Solutions
  • Jill Fiedler-Kelly
    President - Clinical Pharmacology and Pharmacometric Services
  • Brett Howell
    President - Quantitative Systems Pharmacology Solutions
  • Sandra Suarez Sharp
    President - Regulatory Strategies
  • Dan Szot
    Chief Revenue Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.